Validation of Minimally Invasive Ultrasound Indicator Dilution Technique in Critically Ill Children
Validation of a Novel, Minimally Invasive Ultrasound Indicator Dilution Technique for Measuring Cardiac Index in Critically Ill Children
2 other identifiers
observational
9
1 country
1
Brief Summary
A novel method to measure cardiac index based on ultrasound indicator dilution technology (UIDT) has been developed by Transonic Systems Inc. (Ithaca, NY, USA). The method overcomes many of the limitations that have plagued the existing techniques used to measure cardiac index in critically ill children. In the proposed investigation, the investigators hope to validate a novel application of an existing technology in critically ill infants and children. The primary aim of this study is to determine the accuracy of cardiac index measured by UIDT when compared to the gold-standard Fick technique. The primary hypothesis is that the average of three consecutive measurements of cardiac index by UIDT will be accurate when compared to the Fick technique. Secondary aims will be to determine the precision of the measurement, the feasibility of the technique with regards to time required and any complications encountered. An exploratory secondary aim of this study is to determine whether central blood volume (CBV) derived from indicator transit time (ITT) correlates with central venous pressure (CVP) and echocardiography derived measures of preload.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jun 2008
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2008
CompletedFirst Submitted
Initial submission to the registry
February 25, 2009
CompletedFirst Posted
Study publicly available on registry
February 26, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2011
CompletedMay 27, 2016
May 1, 2016
2.9 years
February 25, 2009
May 25, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To determine the accuracy of cardiac index measured by ultrasound dilution when compared to the gold-standard Fick technique.
5-8 minutes minimum
Secondary Outcomes (1)
To determine the precision and feasibility of the measurements. Also to determine whether central blood volume (CBV) measured by ultrasound dilution correlates with central venous pressure (CVP) and echocardiography derived preload measures.
5-8 minutes minimum
Eligibility Criteria
Pediatric patients (less than 18 years of age) with in situ arterial and central venous catheters.
You may qualify if:
- Age: less than 18 years.
- Admission to the CICU (Cardiac Intensive Care Unit) (8S) or MISICU (Medical-Surgical Intensive Care Unit) (7S) of the Children's Hospital Boston.
- Presence of a central venous catheter with its tip in the superior vena cava or a catheter in the pulmonary artery, documented by radiography.
- Requirement for mechanical ventilation via an endotracheal or tracheostomy tube.
- Presence of an arterial catheter.
- Patients must have a two ventricle circulation.
You may not qualify if:
- Endotracheal tube leak of greater than 10%.
- A significant air leak around the endotracheal tube makes VO2 impossible to measure.
- Presence of relevant intracardiac shunt.
- Intracardiac shunt will decrease the area under the arterial dilution curve unpredictably, making cardiac index calculations unreliable.
- A patent foramen ovale and a single ventricular septal defect less than or equal to 2mm or an atrial septal defect less than or equal to 3mm will be considered irrelevant for the purposes of this study.
- Previous enrollment in an incompatible research study.
- Current or prior diagnosis of heparin induced thrombocytopenia.
- A small amount of heparin is required to flush the extracorporeal AV (Arteriovenous) loop that is required for the measurements.
- Pneumothorax with ongoing air leak.
- An air leak will invalidate the measurement of VO2.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Children's Hospital Boston
Boston, Massachusetts, 02115, United States
Related Publications (1)
Krivitski NM, Kislukhin VV, Thuramalla NV. Theory and in vitro validation of a new extracorporeal arteriovenous loop approach for hemodynamic assessment in pediatric and neonatal intensive care unit patients. Pediatr Crit Care Med. 2008 Jul;9(4):423-8. doi: 10.1097/01.PCC.0b013e31816c71bc.
PMID: 18496416BACKGROUND
Study Officials
- PRINCIPAL INVESTIGATOR
Satish Rajagopal, MD
Boston Children's Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 25, 2009
First Posted
February 26, 2009
Study Start
June 1, 2008
Primary Completion
May 1, 2011
Study Completion
May 1, 2011
Last Updated
May 27, 2016
Record last verified: 2016-05
Data Sharing
- IPD Sharing
- Will not share